BNC Wealth Management LLC increased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 110.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,379 shares of the biotechnology company's stock after purchasing an additional 5,456 shares during the quarter. Axon Enterprise accounts for about 1.5% of BNC Wealth Management LLC's investment portfolio, making the stock its 21st largest holding. BNC Wealth Management LLC's holdings in Axon Enterprise were worth $4,147,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in AXON. Blue Trust Inc. grew its position in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company's stock worth $27,000 after acquiring an additional 79 shares during the last quarter. Quent Capital LLC grew its position in Axon Enterprise by 1,875.0% in the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company's stock valued at $32,000 after buying an additional 75 shares in the last quarter. Asset Dedication LLC bought a new position in Axon Enterprise in the 2nd quarter valued at about $47,000. Friedenthal Financial bought a new position in Axon Enterprise in the 3rd quarter valued at about $51,000. Finally, Cullen Frost Bankers Inc. bought a new position in Axon Enterprise in the 2nd quarter valued at about $59,000. Institutional investors own 79.08% of the company's stock.
Axon Enterprise Trading Up 1.8 %
NASDAQ:AXON traded up $8.28 on Thursday, reaching $467.80. The company's stock had a trading volume of 359,335 shares, compared to its average volume of 520,411. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.52 and a current ratio of 2.88. The firm has a market cap of $35.35 billion, a PE ratio of 121.25, a PEG ratio of 10.99 and a beta of 0.94. The business's 50-day moving average price is $407.26 and its two-hundred day moving average price is $343.94. Axon Enterprise, Inc. has a 1-year low of $212.88 and a 1-year high of $471.00.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. The firm had revenue of $504.00 million during the quarter, compared to analysts' expectations of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business's quarterly revenue was up 34.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.80 earnings per share. Equities research analysts anticipate that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.
Analysts Set New Price Targets
AXON has been the subject of a number of recent analyst reports. The Goldman Sachs Group increased their target price on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a "buy" rating in a research report on Wednesday, October 23rd. Northland Securities raised their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an "outperform" rating in a research report on Thursday, August 8th. Bank of America began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They issued a "buy" rating and a $380.00 target price on the stock. Jefferies Financial Group began coverage on shares of Axon Enterprise in a report on Wednesday, July 17th. They set a "buy" rating and a $385.00 target price for the company. Finally, Robert W. Baird upped their price target on Axon Enterprise from $440.00 to $460.00 and gave the company an "outperform" rating in a report on Monday. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $392.85.
Get Our Latest Report on Axon Enterprise
Insiders Place Their Bets
In other news, Director Michael Garnreiter sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares of the company's stock, valued at $11,500,916.82. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, Director Michael Garnreiter sold 1,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $437.98, for a total transaction of $437,980.00. Following the sale, the director now directly owns 26,259 shares of the company's stock, valued at approximately $11,500,916.82. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jeri Williams sold 110 shares of the business's stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $400.00, for a total value of $44,000.00. Following the transaction, the director now directly owns 1,934 shares of the company's stock, valued at approximately $773,600. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 371,172 shares of company stock valued at $137,000,162 in the last 90 days. 5.70% of the stock is currently owned by insiders.
Axon Enterprise Profile
(
Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
Before you consider Axon Enterprise, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axon Enterprise wasn't on the list.
While Axon Enterprise currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.